Cannabis and Burn Pain
Biologically plausible but clinically unproven; not a replacement for standard burn care.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis is biologically plausible for burn pain because cannabinoid receptors are present in skin and pain pathways. But there are no large clinical trials for burns specifically. What we have are case reports, small studies borrowed from other pain types, and marketing claims. Standard burn care (opioids, ketamine, regional anesthesia) has decades of evidence. Don't self-treat open burns with topical CBD or cannabis oils—infection risk is real, and your burn team needs to know what you're taking.
Not medical advice
This article is not medical advice. Burn injuries—especially second-degree and deeper, or burns covering more than a small area—are medical emergencies. If you or someone else has a serious burn, contact emergency services or a burn center. Do not apply cannabis products, oils, or 'CBD salves' to fresh open burns in place of standard wound care. Talk to a qualified clinician (ideally one familiar with burn medicine) before adding any cannabinoid to a treatment plan, especially alongside opioids, benzodiazepines, or ketamine.
Plain-language summary
Burn pain has three overlapping phases: acute nociceptive pain (the tissue damage itself), procedural pain (dressing changes, debridement, physiotherapy), and chronic post-burn pain that is often neuropathic and accompanied by intense itch. Standard care leans on opioids, ketamine, gabapentinoids, regional anesthesia, and antihistamines, with significant side effects and incomplete response in many patients Strong evidence[1][2].
Cannabinoids—primarily THC and CBD—act on the endocannabinoid system, which is present in skin, peripheral nerves, and central pain pathways Strong evidence[3]. That biological story is real. The clinical story is much smaller: a few case reports, small observational studies, and trials borrowed from other pain conditions. There is no large randomized controlled trial of cannabis specifically for burn pain No data.
What probably works
Nothing in the cannabis category has crossed the bar of 'probably works' for burn pain specifically.
What does probably work for burn pain in general—and is the comparator any cannabinoid would need to beat or complement—includes opioids, ketamine, regional anesthesia, gabapentin/pregabalin for neuropathic components, and structured non-pharmacological interventions like virtual reality during dressing changes Strong evidence[1][2][4].
What might work (weak evidence)
Chronic neuropathic post-burn pain. Cannabinoids have modest evidence in chronic neuropathic pain from other causes (HIV neuropathy, multiple sclerosis, post-traumatic neuropathy). A 2018 Cochrane systematic review of cannabis-based medicines for chronic neuropathic pain in adults found small benefits with significant adverse effects Weak / limited[5]. Burn-related neuropathic pain shares mechanistic features with these conditions, so extrapolation is biologically reasonable but remains unproven in burn populations.
Post-burn itch (pruritus). Pruritus affects a majority of burn survivors and is often refractory to standard antihistamines. Small studies of topical creams containing palmitoylethanolamide (PEA), an endocannabinoid-related lipid, have reported reductions in itch severity Weak / limited[6]. PEA is not THC or CBD but shares signaling pathways. Oral cannabinoids have been tried for refractory pruritus in case series with mixed results Anecdote.
Opioid sparing. Observational data from chronic pain populations suggest some patients reduce opioid use when cannabis is added Weak / limited[7]. Whether this transfers to acute burn care—where opioid doses are high and rapidly titrated—is not established.
Anxiety and sleep during recovery. Burn recovery involves prolonged hospitalization, high PTSD risk, and sleep disturbance. Cannabinoids have modest, inconsistent evidence for anxiety and sleep outcomes in general populations Weak / limited[8], but no burn-specific data.
What doesn't work or has weak/no evidence
Topical CBD oil on fresh open burns. Widely marketed. Not supported by clinical evidence. Carrier oils can trap heat, introduce contaminants into open wounds, and interfere with assessment of burn depth and infection No data.
Cannabis 'accelerates wound healing.' There is preclinical work (cell culture and rodent models) suggesting cannabinoid receptors are involved in skin repair and re-epithelialization Weak / limited[9]. There is no robust human trial showing that applying or ingesting cannabinoids speeds burn wound healing No data.
Smoked cannabis for acute burn pain. No controlled evidence. Smoke inhalation is contraindicated in patients with any inhalation injury, which is common in fire/smoke exposure and complicates respiratory status No data.
'Indica strains are better for pain.' This is marketing folklore. The indica/sativa botanical classification does not reliably predict cannabinoid chemistry or subjective effects Disputed[10]. Strain names are not standardized and may refer to different genetics in different dispensaries.
Specific THC:CBD ratios for burns. No burn-specific ratio has been validated in clinical trials. Claims otherwise are extrapolation without evidence No data.
What we don't know
- Whether adjunctive cannabinoids reduce opioid requirements during acute burn hospitalization.
- Whether topical cannabinoid formulations help re-epithelialized (closed) burn scars with pruritus or hypertrophic scarring.
- Optimal dose, route, timing, and formulation—every published case is essentially a different protocol.
- Interactions with the heavy polypharmacy of burn ICU care (opioids, ketamine, benzodiazepines, propofol, anticoagulants metabolized via CYP enzymes that CBD inhibits).
- Effects on infection risk in immunocompromised burn patients.
- Efficacy in children with burns (most cannabis data come from adults).
These are not rhetorical gaps. They are the actual reasons burn societies have not endorsed cannabis as standard care.
Comparison with standard treatments
| Treatment | Evidence for burn pain | Typical role |
|---|---|---|
| Opioids (morphine, fentanyl) | Strong | First-line acute and procedural |
| Ketamine | Strong | Procedural, opioid-sparing |
| Regional anesthesia (nerve blocks, epidural) | Strong | Large burns, grafting |
| Gabapentinoids (gabapentin, pregabalin) | Moderate | Neuropathic and itch components |
| Antihistamines, doxepin, gabapentin | Moderate | Pruritus |
| Virtual reality, hypnosis | Moderate | Non-drug adjunct, especially dressing changes |
| Cannabinoids (oral THC/CBD) | Weak | Possible adjunct in chronic phase; not standard |
| Topical cannabinoids on open wounds | None | Not recommended |
The honest framing: cannabis is, at best, an adjunct to consider in the chronic phase for patients with neuropathic pain or itch that has failed first-line therapy. It is not a replacement for any pillar of standard burn analgesia.
Risks and drug interactions
Drug interactions. CBD inhibits CYP3A4 and CYP2C19, affecting levels of many drugs used in burn care, including warfarin, apixaban, some anticonvulsants, and certain sedatives Strong evidence[11]. Cannabis and Polypharmacy Risks covers this in detail.
Sedation stacking. Adding cannabinoids to opioids, benzodiazepines, and ketamine increases sedation and respiratory depression risk—particularly dangerous in patients with smoke inhalation or requiring mechanical ventilation.
Inhalation. Smoking or vaping is contraindicated in anyone with airway injury, carbon monoxide exposure, or ongoing respiratory compromise, which is common after fire/smoke exposure.
Wound contamination. Non-sterile topical products on open burns carry infection risk. Burn wounds are a known portal for serious infection (Pseudomonas, Staphylococcus aureus, fungi), and burn patients are immunocompromised.
Tachycardia and hypotension. THC can cause both, complicating fluid resuscitation and hemodynamic management in large burns Weak / limited.
Psychiatric effects. Burn patients are at high risk for PTSD, anxiety, and delirium. THC can worsen anxiety and precipitate psychosis in vulnerable patients Weak / limited[12]. THC Dose and Anxiety discusses dose-dependent effects.
Cannabinoid hyperemesis syndrome. In heavy chronic users, paradoxical vomiting complicates recovery and nutrition during the prolonged healing phase.
These risks are manageable in a clinical setting with disclosure and monitoring. They are not manageable when patients self-treat without telling their burn team.
Bottom line
Cannabis is biologically plausible for several aspects of burn pain and itch, particularly in the chronic phase. The clinical evidence is weak and almost entirely extrapolated from other pain conditions. It should not replace standard burn analgesia, should not be applied to open burns as a topical, and should be disclosed to your burn team if used. If you have a serious burn, seek immediate medical care. If you want to learn more on the underlying pharmacology and pain mechanisms, see Cannabis and Neuropathic Pain, Cannabis and Chronic Pain, and Cannabis and Pruritus (Itch).
Sources
- Peer-reviewed Griggs C, Goverman J, Bittner EA, Levi B. Sedation and pain management in burn patients. Clinics in Plastic Surgery. 2017;44(3):535–540.
- Peer-reviewed James DL, Jowza M. Principles of burn pain management. Clinics in Plastic Surgery. 2017;44(4):737–747.
- Peer-reviewed Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences. 2009;30(8):411–420.
- Peer-reviewed Scapin SQ, Echevarría-Guanilo ME, Boeira Fuculo Junior PR, et al. Virtual reality in the treatment of burn patients: A systematic review. Burns. 2018;44(6):1403–1416.
- Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;3:CD012182.
- Peer-reviewed Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). Journal of the European Academy of Dermatology and Venereology. 2008;22(1):73–82.
- Peer-reviewed Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. The Journal of Pain. 2016;17(6):739–744.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Wang LL, Zhao R, Li JY, et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. European Journal of Pharmacology. 2016;786:128–136.
- Peer-reviewed Watts SE, Vidaurre J, Goldberg E, et al. The cannabis conundrum: thinking outside the THC box. Journal of Clinical Pharmacology. 2021;61(3):282–289.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry. 2019;6(5):427–436.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Chronic Pain — Evidence summary of cannabis for chronic pain: modest benefit for some, real risks, and ho...
- Cannabis and Complex Regional Pain Syndrome — Examining the evidence gap and practical role of cannabis in CRPS management.
- Cannabis and Neuropathic Pain — Modest efficacy for some neuropathic pain types; best evidence is short-term and third-lin...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Post-Surgical Pain — Research on cannabinoids for acute post-surgical pain is limited and mixed; standard multi...
- Cannabis and Pruritus (Itch) — What the evidence says about cannabis for chronic itch and when to see a dermatologist.
- Cannabis and Sickle Cell Pain — Limited evidence suggests cannabis may reduce pain interference in sickle cell disease, bu...
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...